The role of bDMARDs in the prevention and treatment of inflammatory-related comorbidities in Psoriatic Arthritis.

Francesco CasoMauro FaticaMario FerraioliMatteo MegnaLuca PotestioAngelo RuggieroNello TommasinoFrancesco MaioneRaffaele ScarpaMaria Sole ChimentiLuisa Costa

Published in: Expert opinion on biological therapy (2024)

Tailoring therapeutic strategies to the individual characteristics of each PsA patient can be an effective approach to manage comorbidities, maximizing the efficacy of bDMARDs, and reducing the incidence of AEs. Identifying targets within disease pathways can guide research into therapeutics that address both PsA and comorbidities simultaneously, but more studies are advocated for clarifying the potential prevention and management of bDMARDs used for PsA.

Keyphrases

prostate cancer
radical prostatectomy
risk factors
oxidative stress
small molecule
human health
risk assessment
drug induced